Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
about
Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunityCancer vaccines: the next generation of tools to monitor the anticancer immune response.Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma modelsMinimizing the immunogenicity of antibodies for clinical application.Mycophenolate mofetil in a case of relapsed, refractory thrombotic thrombocytopenic purpura.Rituximab in the treatment of autoimmune haematological disorders.Repeated courses of rituximab in chronic ITP: Three different regimens.Updated cardiac concerns with rituximab use: A growing challengeA case report of iatrogenic cutaneous Kaposi sarcoma due to rituximab therapy for thrombotic thrombocytopenic purpura.Phylogenetic analysis of the MS4A and TMEM176 gene familiesType 1 diabetes research: Newer approaches and exciting developments.Rituximab-associated interstitial lung disease in fibrillary glomerulonephritis.Medical applications of leukocyte surface molecules--the CD moleculesRituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphomaImmune recognition of self in immunity against cancer.B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseasesCell therapy for autoimmune diseases: does it have a future?Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer.Rapid-infusion rituximab in lymphoma treatment: 2-year experience in a single institution.An uncommon clinical presentation of retroperitoneal non-Hodgkin lymphoma successfully treated with chemotherapy: a case report.Treatment of children and adolescents with multiple sclerosis.Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins.Rituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy.Targeting CD22 reprograms B-cells and reverses autoimmune diabetes.Emerging therapies for multiple sclerosis.Follicular B cells in thyroids of mice with spontaneous autoimmune thyroiditis contribute to disease pathogenesis and are targets of anti-CD20 antibody therapy.Review of the safety and feasibility of rapid infusion of rituximab.Innovative monoclonal antibody therapies in multiple sclerosis.Rituximab-induced interstitial lung disease: case report and literature review.B cells participate in tolerance and autoimmunity through cytokine production.Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature.Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus.Lack of HER-2 gene amplification in non-Hodgkin lymphoma using chromogenic in situ hybridisation test.Rituximab-induced interstitial lung disease: five case reports.Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients.B-cell subsets, signaling and their roles in secretion of autoantibodies.Persistent memory B cell down-regulation after 6-year remission induced by rituximab therapy in patients with systemic lupus erythematosus.
P2860
Q22306446-E13C9741-735E-45CC-8405-C60FB3EE8081Q24814450-6EC15CAF-0469-4421-9877-044B03B000D3Q27312250-B48E5570-DF50-46E1-B731-8F987C9C2A8EQ31150735-BE88249D-A983-449C-9598-F475A3D5CE09Q33374400-2CAAD807-8DB8-4594-BFCC-DE6DC4CFBE66Q33378854-DA311AC8-BC89-403A-AC35-5F12F0006B17Q33386117-1CD0899E-D0D2-4FCA-BE75-251171E71FAFQ33436077-8E55F184-8C63-4E1A-987D-9B6AE358D88DQ33437097-500E568B-95F5-4581-8558-8E585A351FBDQ33534692-DC67337F-04E9-4CBA-A045-7E4A83B05BDCQ33616052-D655A234-624C-4B78-AA1A-EA469EF3ACD5Q35626535-630E6E80-FD6B-4614-B3CA-C28200E1E666Q35690889-D58D7F2E-2367-4876-BF96-D4F669874199Q35848116-9BCED02B-1EDA-4495-9CC3-ACAA31C09867Q35848351-07AD669D-9858-464F-B895-D239C3BCF9AAQ35864865-D8366848-274D-49F6-B624-5184AAD6122BQ35903957-FA5A2E5D-9752-47B4-87AC-4E984872B8CBQ35916008-07260249-445E-4A2C-8B69-C1896499DD9FQ36066311-5349236B-2829-4472-8B86-3E1A4ABD9627Q36095143-757B043E-D02D-44D9-9705-9D05CFA28F9DQ36140335-8CB0F839-3126-45E4-86B6-9EDB970A458AQ36153390-E51D0FB2-DE6B-4C40-BB9C-32705A34A12AQ36269613-06663512-E3DE-4B4D-A134-AD534CCC3A21Q36607310-8D57E29C-2B69-4F83-B575-E764FB40AD65Q36943737-F09519A7-8E56-4CBD-9EDD-9443C0EDB7A1Q36963208-E025AA90-3EB7-43D2-AC95-010FF860DB77Q37512037-AC6F7190-DA34-4E28-A00A-2C2991FCAD15Q37769107-F071C9A8-F287-421B-AFF1-FF01C19250E4Q37823315-63E5A1AD-DF80-411F-B4A6-8CC3F65FF721Q37879885-901C269B-B1A4-415C-8982-B602735DE864Q38163603-D5DB276C-1006-455D-8B01-DABA46990213Q38243214-B4D7C3C8-E67D-4A55-8597-9BDDE60120A2Q38306720-09F7F7B6-07F9-4471-9895-E4048F4C5A27Q39978523-80D194DE-2427-4D9B-9542-49CEAA4CA47FQ43192625-9F7ECE58-2264-47AE-99DF-600EED37FB0EQ45411301-AD2B2268-D138-42D2-9BBB-ED4B89E9C5E3Q45855065-5289E694-6366-4D86-9B4C-4E872B3C42D1Q46830791-64B50101-7AD2-48AC-8C77-DB7CD1601639Q50645188-A10D2EC4-0684-46FC-B33B-2840B12CC780Q50913061-0DEF2ABD-093F-4DBF-B2CC-250A3E7E76FB
P2860
Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
@ast
Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
@en
type
label
Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
@ast
Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
@en
prefLabel
Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
@ast
Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
@en
P2093
P1476
Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
@en
P2093
Arturo Molina
Christine A White
William Rastetter
P304
P356
10.1146/ANNUREV.MED.55.091902.104249
P577
2004-01-01T00:00:00Z